Alpha Teknova Q3 revenue beats expectations, helped by lab essentials products sales

Alpha Teknova

06/11/2025 21:33

Overview

Alpha Teknova Q3 revenue up 9% yr/yr, beating analyst expectations

Company reaffirms 2025 revenue guidance of $39-42 mln

Gross margin improved to 30.7% from 0.9% due to prior yr non-recurring charges

Outlook

Alpha Teknova reaffirms 2025 revenue guidance of $39-42 mln

Company anticipates 2025 Free Cash Outflow of less than $12 mln

Teknova sees long-term growth from customer relationships and product diversity

Result Drivers

LAB ESSENTIALS GROWTH - Revenue from Lab Essentials products increased, offsetting lagging Clinical Solutions sales

CUSTOMER RELATIONSHIPS - Rising number of Clinical Solutions customers despite challenging funding environment

OPERATIONAL PERFORMANCE - Improved operational performance contributed to revenue growth, per CFO Matt Lowell

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$10.45 mln
$10.30 mln (5 Analysts)
Q3 EPS
-$0.08
Q3 Net Income
-$4.29 mln
Q3 Gross Profit
$3.21 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Alpha Teknova Inc is $10.00, about 50.5% above its November 5 closing price of $4.95

Press Release: ID:nGNXb3hCc7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)